미국, 일본, 유럽의 의약품 생애주기 데이터 구축 및 활용 현황
Development and Utilization of Drug Lifecycle Data in the United States, Japan, and Europe
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: With the growing interest in big data, regulatory agencies in United States, Japan, and Europe are showing active movements to use RWD and RWE to manage drug safety and development activation. Along with the global movements, it is necessary to establish a basic system for utilizing RWD based drug lifecycle data for drug safety management in Korea. The purpose of this study is to review and find implication of the collection and uti- lization of drug lifecycle data in the U.S., Japan, and Europe. Methods: In order to investigate the current status and contents of each country’s system, we searched the websites of each country’s regulatory agency and related agencies, and collected and investigated related laws, papers, and reports. We compared and analyzed focusing on solving regulatory problems that may occur in the drug lifecycle or exploring the safety and potential effects of drugs in drug lifecycle phases. Results: Based on FDA Sentinel 5-year plan and MID-NET, the U.S. and Japan are accelerating the generation of real data and real evidence for regulatory decision-making in post-marketing safety management. In Europe, various clinical field-specific projects have been undertaken to assess the effectiveness and safety of drugs due to disease. Various research cases using drug lifecycle data collected from drug safety management systems in each country have been represented. Conclusions: By identifying drug safety management systems and cases of drug lifecycle data utilization in various countries, we expect to serve as a stepping stone for discussions on the direction and utilization plan to efficiently develop drug safety management systems in Korea.
Abstract
Objectives: With the growing interest in big data, regulatory agencies in United States, Japan, and Europe are showing active movements to use RWD and RWE to manage drug safety and development activation. Along with the global movements, it is necessary to establish a basic system for utilizing RWD based drug lifecycle data for drug safety management in Korea. The purpose of this study is to review and find implication of the collection and uti- lization of drug lifecycle data in the U.S., Japan, and Europe. Methods: In order to investigate the current status and contents of each country’s system, we searched the websites of each country’s regulatory agency and related agencies, and collected and investigated related laws, papers, and reports. We compared and analyzed focusing on solving regulatory problems that may occur in the drug lifecycle or exploring the safety and potential effects of drugs in drug lifecycle phases. Results: Based on FDA Sentinel 5-year plan and MID-NET, the U.S. and Japan are accelerating the generation of real data and real evidence for regulatory decision-making in post-marketing safety management. In Europe, various clinical field-specific projects have been undertaken to assess the effectiveness and safety of drugs due to disease. Various research cases using drug lifecycle data collected from drug safety management systems in each country have been represented. Conclusions: By identifying drug safety management systems and cases of drug lifecycle data utilization in various countries, we expect to serve as a stepping stone for discussions on the direction and utilization plan to efficiently develop drug safety management systems in Korea.
참고문헌 (31)
- Food and Drug Administration, "Submitting documents utilizing realworld data and real-world evidence to FDA for drugs and biologics" (2019), Food and Drug Administration
- Duke Margolis Center for Health Policy, "A framework for regulatory use of real-world evidence" (2017), Duke Margolis Center for Health Policy
- Dong Wook Shin, "Disparities in Cervical Cancer Screening Among Women With Disabilities: A National Database Study in South Korea", Journal of Clinical Oncology, 36(27), pp.2778~2786 (2018), American Society of Clinical Oncology (ASCO)[DOI]
- Kim L, "A guide for the utilization of HIRA national patient samples", National Health Insurance Service, ~ (2020)
- "National cancer registration program"[URL]
- Soo Lim, "Increasing Prevalence of Metabolic Syndrome in Korea", Diabetes Care, 34(6), pp.1323~1328 (2011), American Diabetes Association[DOI]
- Yang Wha Kang, "Korea Community Health Survey Data Profiles", Osong Public Health and Research Perspectives, 6(3), pp.211~217 (2015), 질병관리청
- Food and Drug Administration, "The framework for FDA’s real-world evidence program" (2018), Food and Drug Administration
- Pharmaceuticals and Medical Devices Agency, , The 6th joint conference of Japan and Taiwan on medical products regulation (2018)
- European Medicines Agency, "EU medicines agencies network strategy to 2020" (2015), European Medicines Agency
- Food and Drug Administration, "Sentinel System five-year strategy:2019-2023" (2019), Food and Drug Administration
- Food and Drug Administration, "CBER interim strategic plan FY 2017-2019" (2016), Food and Drug Administration
- "Outline of post-marketing safety measures"[URL]
- Chieko Ishiguro, "The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan", Pharmacoepidemiology and Drug Safety, 25(7), pp.854~859 (2016), Wiley[DOI]
- 박한희, "미국, 유럽, 일본의 실사용데이터 연구사업 추진현황과 시사점", 약 학 회 지, 64(1), pp.54~64 (2020), 대한약학회[DOI]
- Mitsune Yamaguchi, "Establishment of the MID‐NET<sup>®<", sup> medical information database network as a reliable and valuable database for drug safety assessments in Japan, 2019, pp.28(10), 1395~1404[DOI]
- Yamaguchi M, "Epidemiologic research on realworld medical data in Japan", pp.41~49 (2022), Springer
- European Medicines Agency, "EMA regulatory science to 2025-strategic reflection" (2020), European Medicines Agency
- Noelle M. Cocoros, "A COVID‐19‐ready public health surveillance system: The Food and Drug Administration’s sentinel system", Pharmacoepidemiology and Drug Safety, 30(7), pp.827~837 (2021), Wiley[DOI]
- Kathleen E. Walsh, "Validation of anaphylaxis in the Food and Drug Administration's Mini‐Sentinel", Pharmacoepidemiology and Drug Safety, 22(11), pp.1205~1213 (2013), Wiley[DOI]
- J. Matthew Brennan, "Safety and clinical effectiveness of drug‐eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare‐linked National Cardiovascular Data Registry<sup>®<", sup> Cath<scp>PCI<, sup> (2005–2009), pp.Catheterization and Cardiovascular Interventions, 2015[DOI]
- ), "The American Journal of Cardiology", 2006, 1478~1481, pp.Elsevier BV, 10.1016[DOI]
- Emmanuel M. Baah, "Analysis of Data on Adverse Drug Events Reported to the Food and Drugs Administration of the United States of America", Open Journal of Statistics, 10(02), pp.203~227 (2020), Scientific Research Publishing, Inc.[DOI]
- Karen Smith, "Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab", Drug Safety, 41(12), pp.1397~1410 (2018), Springer Science and Business Media LLC[DOI]
- Sarah Mofid, "Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA", Clinical Therapeutics, 44(2), pp.306~322 (2022), Elsevier BV[DOI]
- Yukiko Hashitera, "Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market", Drug Discovery Today, 18(21-22), pp.1109~1116 (2013), Elsevier BV[DOI]
- Kenji Kawasumi, "Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study", Molecular and Clinical Oncology, 14(1) (2020), Spandidos Publications[DOI]
- Masahiko Suzuki, "Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database", eNeurologicalSci, 20, pp.100257~ (2020), Elsevier BV[DOI]
- Takeru Shiroiwa, "Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan", International Journal of Technology Assessment in Health Care, 36(3), pp.270~276 (2020), Cambridge University Press (CUP)[DOI]
- Floriane Montanari, "Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning", Journal of Cheminformatics, 8(1) (2016), Springer Science and Business Media LLC[DOI]
- Ricard Garcia-Serna, "Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms", Chemical Research in Toxicology, 28(10), pp.1875~1887 (2015), American Chemical Society (ACS)[DOI]